{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T11:12:15Z","timestamp":1740136335635,"version":"3.37.3"},"reference-count":75,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2023,7,5]],"date-time":"2023-07-05T00:00:00Z","timestamp":1688515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,7,5]],"date-time":"2023-07-05T00:00:00Z","timestamp":1688515200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Sci"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1007\/s10072-023-06933-3","type":"journal-article","created":{"date-parts":[[2023,7,5]],"date-time":"2023-07-05T02:02:00Z","timestamp":1688522520000},"page":"3877-3884","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Circulating miRNAs drive personalized medicine based on subgroup classification in myasthenia gravis patients"],"prefix":"10.1007","volume":"44","author":[{"given":"Xiaoyu","family":"Huang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhouao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yingying","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mingming","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xue","family":"Du","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0993-6994","authenticated-orcid":false,"given":"Yong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,7,5]]},"reference":[{"issue":"26","key":"6933_CR1","doi-asserted-by":"publisher","first-page":"2570","DOI":"10.1056\/NEJMra1602678","volume":"375","author":"NE Gilhus","year":"2016","unstructured":"Gilhus NE (2016) Myasthenia gravis. N Engl J Med 375(26):2570\u20132581","journal-title":"N Engl J Med"},{"issue":"5","key":"6933_CR2","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1097\/WCO.0000000000000596","volume":"31","author":"R Mantegazza","year":"2018","unstructured":"Mantegazza R, Bernasconi P, Cavalcante P (2018) Myasthenia gravis: from autoantibodies to therapy. Curr Opin Neurol 31(5):517\u2013525","journal-title":"Curr Opin Neurol"},{"issue":"5","key":"6933_CR3","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1038\/nrneurol.2016.44","volume":"12","author":"NE Gilhus","year":"2016","unstructured":"Gilhus NE, Skeie GO, Romi F et al (2016) Myasthenia gravis - autoantibody characteristics and their implications for therapy. Nat Rev Neurol 12(5):259\u2013268","journal-title":"Nat Rev Neurol"},{"issue":"10","key":"6933_CR4","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/S1474-4422(15)00145-3","volume":"14","author":"NE Gilhus","year":"2015","unstructured":"Gilhus NE, Verschuuren JJ (2015) Myasthenia gravis: subgroup classification and therapeutic strategies. Lancet Neurol 14(10):1023\u20131036","journal-title":"Lancet Neurol"},{"issue":"5","key":"6933_CR5","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/S1474-4422(09)70063-8","volume":"8","author":"MN Meriggioli","year":"2009","unstructured":"Meriggioli MN, Sanders DB (2009) Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity. Lancet Neurol 8(5):475\u2013490","journal-title":"Lancet Neurol"},{"issue":"4","key":"6933_CR6","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1177\/0300985813502820","volume":"51","author":"M Bhaskaran","year":"2014","unstructured":"Bhaskaran M, Mohan M (2014) MicroRNAs: history, biogenesis, and their evolving role in animal development and disease. Vet Pathol 51(4):759\u2013774","journal-title":"Vet Pathol"},{"issue":"11","key":"6933_CR7","doi-asserted-by":"publisher","first-page":"554","DOI":"10.5483\/BMBRep.2017.50.11.179","volume":"50","author":"D Kim","year":"2017","unstructured":"Kim D, Chang HR, Baek D (2017) Rules for functional microRNA targeting. BMB Rep 50(11):554\u2013559","journal-title":"BMB Rep"},{"issue":"10","key":"6933_CR8","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1016\/j.cub.2009.03.059","volume":"19","author":"H Seitz","year":"2009","unstructured":"Seitz H (2009) Redefining microRNA targets. Curr Biol 19(10):870\u2013873","journal-title":"Curr Biol"},{"issue":"3","key":"6933_CR9","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1038\/ncb0309-228","volume":"11","author":"J Winter","year":"2009","unstructured":"Winter J, Jung S, Keller S et al (2009) Many roads to maturity: microRNA biogenesis pathways and their regulation. Nat Cell Biol 11(3):228\u2013234","journal-title":"Nat Cell Biol"},{"issue":"4","key":"6933_CR10","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1124\/pr.120.019554","volume":"72","author":"AM Yu","year":"2020","unstructured":"Yu AM, Choi YH, Tu MJ (2020) RNA drugs and RNA targets for small molecules: principles, progress, and challenges. Pharmacol Rev 72(4):862\u2013898","journal-title":"Pharmacol Rev"},{"key":"6933_CR11","doi-asserted-by":"publisher","first-page":"102438","DOI":"10.1016\/j.jaut.2020.102438","volume":"109","author":"L Zhang","year":"2020","unstructured":"Zhang L, Wu H, Zhao M et al (2020) Clinical significance of miRNAs in autoimmunity. J Autoimmun 109:102438","journal-title":"J Autoimmun"},{"issue":"3","key":"6933_CR12","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1007\/s10238-015-0358-1","volume":"16","author":"Y Zhang","year":"2016","unstructured":"Zhang Y, Guo M, Xin N et al (2016) Decreased microRNA miR-181c expression in peripheral blood mononuclear cells correlates with elevated serum levels of IL-7 and IL-17 in patients with myasthenia gravis. Clin Exp Med 16(3):413\u2013421","journal-title":"Clin Exp Med"},{"key":"6933_CR13","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.clim.2015.12.009","volume":"164","author":"XF Liu","year":"2016","unstructured":"Liu XF, Wang RQ, Hu B et al (2016) MiR-15a contributes abnormal immune response in myasthenia gravis by targeting CXCL10. Clin Immunol 164:106\u2013113","journal-title":"Clin Immunol"},{"issue":"3","key":"6933_CR14","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1007\/s10875-012-9834-5","volume":"33","author":"Z Cheng","year":"2013","unstructured":"Cheng Z, Qiu S, Jiang L et al (2013) MiR-320a is downregulated in patients with myasthenia gravis and modulates inflammatory cytokines production by targeting mitogen-activated protein kinase 1. J Clin Immunol 33(3):567\u2013576","journal-title":"J Clin Immunol"},{"key":"6933_CR15","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.neulet.2013.09.014","volume":"555","author":"J Lu","year":"2013","unstructured":"Lu J, Yan M, Wang Y et al (2013) Altered expression of miR-146a in myasthenia gravis. Neurosci Lett 555:85\u201390","journal-title":"Neurosci Lett"},{"key":"6933_CR16","doi-asserted-by":"publisher","first-page":"104388","DOI":"10.1016\/j.phrs.2019.104388","volume":"148","author":"P Cavalcante","year":"2019","unstructured":"Cavalcante P, Mizrachi T, Barzago C et al (2019) MicroRNA signature associated with treatment response in myasthenia gravis: a further step towards precision medicine. Pharmacol Res 148:104388","journal-title":"Pharmacol Res"},{"issue":"6","key":"6933_CR17","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1097\/ICU.0000000000000526","volume":"29","author":"E Fortin","year":"2018","unstructured":"Fortin E, Cestari DM, Weinberg DH (2018) Ocular myasthenia gravis: an update on diagnosis and treatment. Curr Opin Ophthalmol 29(6):477\u2013484","journal-title":"Curr Opin Ophthalmol"},{"issue":"1","key":"6933_CR18","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1097\/WNO.0000000000000270","volume":"36","author":"SH Wong","year":"2016","unstructured":"Wong SH, Plant GT, Cornblath W (2016) Does treatment of ocular myasthenia gravis with early immunosuppressive therapy prevent secondarily generalization and should it be offered to all such patients? J Neuroophthalmol 36(1):98\u2013102","journal-title":"J Neuroophthalmol"},{"issue":"2","key":"6933_CR19","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1002\/acn3.692","volume":"6","author":"L Sabre","year":"2019","unstructured":"Sabre L, Maddison P, Wong SH et al (2019) miR-30e-5p as predictor of generalization in ocular myasthenia gravis. Ann Clin Transl Neurol 6(2):243\u2013251","journal-title":"Ann Clin Transl Neurol"},{"key":"6933_CR20","doi-asserted-by":"publisher","first-page":"668760","DOI":"10.3389\/fimmu.2021.668760","volume":"12","author":"T Cheng","year":"2021","unstructured":"Cheng T, Ding S, Liu S et al (2021) Resolvin D1 improves the Treg\/Th17 imbalance in systemic lupus erythematosus through miR-30e-5p. Front Immunol 12:668760","journal-title":"Front Immunol"},{"issue":"2","key":"6933_CR21","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1007\/s00441-020-03373-9","volume":"384","author":"Y Li","year":"2021","unstructured":"Li Y, Yu J, Wang F et al (2021) MiR-150-5p regulate T cell activation in severe aplastic anemia by targeting Bach2. Cell Tissue Res 384(2):423\u2013434","journal-title":"Cell Tissue Res"},{"key":"6933_CR22","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.intimp.2017.11.011","volume":"54","author":"Z Ma","year":"2018","unstructured":"Ma Z, Shen Y, Zeng Q et al (2018) MiR-150-5p regulates EGR2 to promote the development of chronic rhinosinusitis via the DC-Th axis. Int Immunopharmacol 54:188\u2013197","journal-title":"Int Immunopharmacol"},{"issue":"3","key":"6933_CR23","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1684\/ecn.2015.0367","volume":"26","author":"N Chunjie","year":"2015","unstructured":"Chunjie N, Huijuan N, Zhao Y et al (2015) Disease-specific signature of serum miR-20b and its targets IL-8 and IL-25, in myasthenia gravis patients. Eur Cytokine Netw 26(3):61\u201366","journal-title":"Eur Cytokine Netw"},{"issue":"3","key":"6933_CR24","doi-asserted-by":"publisher","first-page":"e450","DOI":"10.1212\/NXI.0000000000000450","volume":"5","author":"CJ Molin","year":"2018","unstructured":"Molin CJ, Sabre L, Weis CA et al (2018) Thymectomy lowers the myasthenia gravis biomarker miR-150-5p. Neurol Neuroimmunol Neuroinflamm 5(3):e450","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"11","key":"6933_CR25","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1016\/j.imbio.2016.06.012","volume":"221","author":"C Barzago","year":"2016","unstructured":"Barzago C, Lum J, Cavalcante P et al (2016) A novel infection- and inflammation-associated molecular signature in peripheral blood of myasthenia gravis patients. Immunobiology 221(11):1227\u20131236","journal-title":"Immunobiology"},{"key":"6933_CR26","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.jneuroim.2018.05.003","volume":"321","author":"L Sabre","year":"2018","unstructured":"Sabre L, Maddison P, Sadalage G (2018) Circulating microRNA miR-21-5p, miR-150-5p and miR-30e-5p correlate with clinical status in late onset myasthenia gravis. J Neuroimmunol 321:164\u2013170","journal-title":"J Neuroimmunol"},{"issue":"3","key":"6933_CR27","doi-asserted-by":"publisher","first-page":"e91927","DOI":"10.1371\/journal.pone.0091927","volume":"9","author":"G Nogales-Gadea","year":"2014","unstructured":"Nogales-Gadea G, Ramos-Fransi A, Su\u00e1rez-Calvet X et al (2014) Analysis of serum miRNA profiles of myasthenia gravis patients. PLoS ONE 9(3):e91927","journal-title":"PLoS ONE"},{"key":"6933_CR28","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.jneuroim.2016.01.003","volume":"292","author":"T Punga","year":"2016","unstructured":"Punga T, Bartoccioni E, Lewandowska M et al (2016) Disease specific enrichment of circulating let-7 family microRNA in MuSK+ myasthenia gravis. J Neuroimmunol 292:21\u201326","journal-title":"J Neuroimmunol"},{"key":"6933_CR29","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.jneuroim.2018.10.003","volume":"325","author":"L Sabre","year":"2018","unstructured":"Sabre L, Guptill JT, Russo M et al (2018) Circulating microRNA plasma profile in MuSK+ myasthenia gravis. J Neuroimmunol 325:87\u201391","journal-title":"J Neuroimmunol"},{"issue":"2","key":"6933_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1615\/CritRevEukaryotGeneExpr.2021037369","volume":"31","author":"Y Tan","year":"2021","unstructured":"Tan Y, Zhu L, Cui L, Guan Y (2021) Differential expression of miRNA in the peripheral blood mononuclear cells in myasthenia gravis with muscle-specific receptor tyrosine kinase antibodies. Crit Rev Eukaryot Gene Expr 31(2):1\u201315","journal-title":"Crit Rev Eukaryot Gene Expr"},{"key":"6933_CR31","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.imlet.2016.02.005","volume":"172","author":"J Li","year":"2016","unstructured":"Li J, Qiu D, Chen Z et al (2016) Altered expression of miR-125a-5p in thymoma-associated myasthenia gravis and its down-regulation of foxp3 expression in Jurkat cells. Immunol Lett 172:47\u201355","journal-title":"Immunol Lett"},{"key":"6933_CR32","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.jneuroim.2015.08.013","volume":"288","author":"Z Wang","year":"2015","unstructured":"Wang Z, Chen Y, Xu S et al (2015) Aberrant decrease of microRNA19b regulates TSLP expression and contributes to Th17 cells development in myasthenia gravis related thymomas. J Neuroimmunol 288:34\u201339","journal-title":"J Neuroimmunol"},{"key":"6933_CR33","doi-asserted-by":"publisher","first-page":"9595718","DOI":"10.1155\/2016\/9595718","volume":"2016","author":"Y Xin","year":"2016","unstructured":"Xin Y, Cai H, Lu T et al (2016) miR-20b inhibits T cell proliferation and activation via NFAT signaling pathway in thymoma-associated myasthenia gravis. Biomed Res Int 2016:9595718","journal-title":"Biomed Res Int"},{"issue":"7","key":"6933_CR34","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1001\/archneur.1991.00530190081019","volume":"48","author":"FE Somnier","year":"1991","unstructured":"Somnier FE, Keiding N, Paulson OB (1991) Epidemiology of myasthenia gravis in Denmark. A longitudinal and comprehensive population survey. Arch Neurol 48(7):733\u2013739","journal-title":"Arch Neurol"},{"issue":"1","key":"6933_CR35","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1080\/01616412.2018.1525121","volume":"41","author":"L Fan","year":"2019","unstructured":"Fan L, Ma S, Yang Y et al (2019) Clinical differences of early and late-onset myasthenia gravis in 985 patients. Neurol Res 41(1):45\u201351","journal-title":"Neurol Res"},{"issue":"7","key":"6933_CR36","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1016\/j.nmd.2017.04.002","volume":"27","author":"E Santos","year":"2017","unstructured":"Santos E, Bettencourt A, da Silva AM et al (2017) HLA and age of onset in myasthenia gravis. Neuromuscul Disord 27(7):650\u2013654","journal-title":"Neuromuscul Disord"},{"issue":"10","key":"6933_CR37","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1016\/S0035-3787(06)75109-8","volume":"162","author":"A Barbaud","year":"2006","unstructured":"Barbaud A, Carlander B, Pag\u00e8s M (2006) Formes tardives de myasth\u00e9nie. Etude comparative avec la myasth\u00e9nie du sujet jeune [Late onset forms of myasthenia gravis. Comparison with early-onset myasthenia gravis]. Rev Neurol (Paris) 162(10):990\u2013996","journal-title":"Rev Neurol (Paris)"},{"issue":"1\u20132","key":"6933_CR38","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.jneuroim.2010.10.023","volume":"230","author":"S Suzuki","year":"2011","unstructured":"Suzuki S, Utsugisawa K, Nagane Y et al (2011) Clinical and immunological differences between early and late-onset myasthenia gravis in Japan. J Neuroimmunol 230(1\u20132):148\u2013152","journal-title":"J Neuroimmunol"},{"issue":"1","key":"6933_CR39","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1111\/nyas.13519","volume":"1412","author":"MA Cron","year":"2018","unstructured":"Cron MA, Maillard S, Villegas J et al (2018) Thymus involvement in early-onset myasthenia gravis. Ann N Y Acad Sci 1412(1):137\u2013145","journal-title":"Ann N Y Acad Sci"},{"issue":"3","key":"6933_CR40","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1111\/ane.13549","volume":"145","author":"E Klimiec-Moskal","year":"2022","unstructured":"Klimiec-Moskal E, Quirke M, Leite MI (2022) Comorbidities in older patients with myasthenia gravis-comparison between early- and late-onset disease. Acta Neurol Scand 145(3):371\u2013374","journal-title":"Acta Neurol Scand"},{"issue":"21","key":"6933_CR41","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1056\/NEJMx170003","volume":"376","author":"GI Wolfe","year":"2017","unstructured":"Wolfe GI, Kaminski HJ, Aban IB et al (2017) Randomized trial of thymectomy in myasthenia gravis. N Engl J Med 376(21):2097","journal-title":"N Engl J Med"},{"issue":"3","key":"6933_CR42","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1212\/WNL.0000000000011124","volume":"96","author":"P Narayanaswami","year":"2021","unstructured":"Narayanaswami P, Sanders DB, Wolfe G et al (2021) International consensus guidance for management of Myasthenia Gravis: 2020 update. Neurology 96(3):114\u2013122","journal-title":"Neurology"},{"issue":"3","key":"6933_CR43","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/S1474-4422(18)30392-2","volume":"18","author":"GI Wolfe","year":"2019","unstructured":"Wolfe GI, Kaminski HJ, Aban IB et al (2019) Long-term effect of thymectomy plus prednisone versus prednisone alone in patients with non-thymomatous myasthenia gravis: 2-year extension of the MGTX randomised trial. Lancet Neurol 18(3):259\u2013268","journal-title":"Lancet Neurol"},{"issue":"1","key":"6933_CR44","doi-asserted-by":"publisher","first-page":"4","DOI":"10.17712\/nsj.2021.1.20190041","volume":"26","author":"F Alqarni","year":"2021","unstructured":"Alqarni F, Almalki D, Aljohani Z et al (2021) Prevalence and risk factors of myasthenia gravis recurrence post-thymectomy. Neurosciences (Riyadh) 26(1):4\u201314","journal-title":"Neurosciences (Riyadh)"},{"issue":"4","key":"6933_CR45","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1093\/ejcts\/ezab253","volume":"60","author":"G Romano","year":"2021","unstructured":"Romano G, Zirafa CC, Ceccarelli I et al (2021) Robotic thymectomy for thymoma in patients with myasthenia gravis: neurological and oncological outcomes. Eur J Cardiothorac Surg 60(4):890\u2013895","journal-title":"Eur J Cardiothorac Surg"},{"issue":"1","key":"6933_CR46","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1002\/acn3.24","volume":"1","author":"T Punga","year":"2014","unstructured":"Punga T, Le Panse R, Andersson M et al (2014) Circulating miRNAs in myasthenia gravis: miR-150-5p as a new potential biomarker. Ann Clin Transl Neurol 1(1):49\u201358","journal-title":"Ann Clin Transl Neurol"},{"key":"6933_CR47","doi-asserted-by":"publisher","first-page":"539","DOI":"10.3389\/fimmu.2019.00539","volume":"10","author":"MA Cron","year":"2019","unstructured":"Cron MA, Maillard S, Truffault F et al (2019) Causes and consequences of miR-150-5p dysregulation in myasthenia gravis. Front Immunol 10:539","journal-title":"Front Immunol"},{"key":"6933_CR48","doi-asserted-by":"publisher","first-page":"142","DOI":"10.3389\/fimmu.2020.00142","volume":"11","author":"F Bortone","year":"2020","unstructured":"Bortone F, Scandiffio L, Marcuzzo S et al (2020) miR-146a in myasthenia gravis thymus bridges innate immunity with autoimmunity and is linked to therapeutic effects of corticosteroids. Front Immunol 11:142","journal-title":"Front Immunol"},{"issue":"2","key":"6933_CR49","doi-asserted-by":"publisher","first-page":"140","DOI":"10.2174\/2211536605666160610094230","volume":"5","author":"S Saravanan","year":"2016","unstructured":"Saravanan S, Islam VI, Thirugnanasambantham K, Sekar D (2016) In silico identification of human miR 3654 and its targets revealed its involvement in prostate cancer progression. Microrna 5(2):140\u2013145","journal-title":"Microrna"},{"key":"6933_CR50","doi-asserted-by":"publisher","first-page":"5744999","DOI":"10.1155\/2022\/5744999","volume":"2022","author":"Y Liu","year":"2022","unstructured":"Liu Y, Hu L, Liu Q et al (2022) miR-3651 participates in the growth cycle of hepatocellular carcinoma cells and promotes the malignant metastasis via the PI3K\/AKT\/mTOR signalling pathway. J Oncol 2022:5744999","journal-title":"J Oncol"},{"issue":"3","key":"6933_CR51","doi-asserted-by":"publisher","first-page":"368504221109212","DOI":"10.1177\/00368504221109212","volume":"105","author":"H Li","year":"2022","unstructured":"Li H (2022) Physiologic and pathophysiologic roles of AKAP12. Sci Prog 105(3):368504221109212","journal-title":"Sci Prog"},{"issue":"3","key":"6933_CR52","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1136\/annrheumdis-2013-203832","volume":"73","author":"JM Cowden","year":"2014","unstructured":"Cowden JM, Yu F, Banie H et al (2014) The histamine H4 receptor mediates inflammation and Th17 responses in preclinical models of arthritis. Ann Rheum Dis 73(3):600\u2013608","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"6933_CR53","doi-asserted-by":"publisher","first-page":"143","DOI":"10.2174\/138955711794519519","volume":"11","author":"C Saravanan","year":"2011","unstructured":"Saravanan C, Bharti SK, Jaggi S et al (2011) Histamine H4 receptor: a novel target for inflammation therapy. Mini Rev Med Chem 11(2):143\u2013158","journal-title":"Mini Rev Med Chem"},{"key":"6933_CR54","doi-asserted-by":"publisher","first-page":"100063","DOI":"10.1016\/j.lanwpc.2020.100063","volume":"5","author":"J Chen","year":"2020","unstructured":"Chen J, Tian DC, Zhang C et al (2020) Incidence, mortality, and economic burden of myasthenia gravis in China: a nationwide population-based study. Lancet Reg Health West Pac 5:100063","journal-title":"Lancet Reg Health West Pac"},{"key":"6933_CR55","doi-asserted-by":"publisher","first-page":"151","DOI":"10.3389\/fimmu.2020.00151","volume":"11","author":"AA Fiorillo","year":"2020","unstructured":"Fiorillo AA, Heier CR, Huang YF et al (2020) Estrogen receptor, inflammatory, and FOXO transcription factors regulate expression of myasthenia gravis-associated circulating microRNAs. Front Immunol 11:151","journal-title":"Front Immunol"},{"issue":"1\u20132","key":"6933_CR56","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.jns.2015.06.019","volume":"356","author":"AR Punga","year":"2015","unstructured":"Punga AR, Andersson M, Alimohammadi M, Punga T (2015) Disease specific signature of circulating miR-150-5p and miR-21-5p in myasthenia gravis patients. J Neurol Sci 356(1\u20132):90\u201396","journal-title":"J Neurol Sci"},{"issue":"10","key":"6933_CR57","doi-asserted-by":"publisher","first-page":"e76217","DOI":"10.1371\/journal.pone.0076217","volume":"8","author":"K Smigielska-Czepiel","year":"2013","unstructured":"Smigielska-Czepiel K, van den Berg A, Jellema P et al (2013) Dual role of miR-21 in CD4+ T-cells: activation-induced miR-21 supports survival of memory T-cells and regulates CCR7 expression in naive T-cells. PLoS ONE 8(10):e76217","journal-title":"PLoS ONE"},{"issue":"4","key":"6933_CR58","doi-asserted-by":"publisher","first-page":"740","DOI":"10.3390\/cells11040740","volume":"11","author":"F Beretta","year":"2022","unstructured":"Beretta F, Huang YF, Punga AR (2022) Towards personalized medicine in myasthenia gravis: role of circulating microRNAs miR-30e-5p, miR-150-5p and miR-21-5p. Cells 11(4):740","journal-title":"Cells"},{"issue":"5","key":"6933_CR59","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1016\/j.immuni.2010.11.010","volume":"33","author":"L Belver","year":"2010","unstructured":"Belver L, de Y\u00e9benes VG, Ramiro AR (2010) MicroRNAs prevent the generation of autoreactive antibodies. Immunity 33(5):713\u2013722","journal-title":"Immunity"},{"issue":"5","key":"6933_CR60","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1002\/hep.22806","volume":"49","author":"WC Tsai","year":"2009","unstructured":"Tsai WC, Hsu PW, Lai TC et al (2009) MicroRNA-122, a tumor suppressor microRNA that regulates intrahepatic metastasis of hepatocellular carcinoma. Hepatology 49(5):1571\u20131582","journal-title":"Hepatology"},{"key":"6933_CR61","doi-asserted-by":"publisher","first-page":"104048","DOI":"10.1016\/j.cellimm.2020.104048","volume":"349","author":"M M\u00e4rklin","year":"2020","unstructured":"M\u00e4rklin M, Heitmann JS, Kauer J et al (2020) Genetic loss of NFAT2 (NFATc1) impairs B cell development of B1 and B2 B cells. Cell Immunol 349:104048","journal-title":"Cell Immunol"},{"issue":"5","key":"6933_CR62","doi-asserted-by":"publisher","first-page":"2345","DOI":"10.4049\/jimmunol.1201591","volume":"190","author":"M Hock","year":"2013","unstructured":"Hock M, Vaeth M, Rudolf R et al (2013) NFATc1 induction in peripheral T and B lymphocytes. J Immunol 190(5):2345\u20132353","journal-title":"J Immunol"},{"issue":"11","key":"6933_CR63","doi-asserted-by":"publisher","first-page":"2131","DOI":"10.1212\/01.WNL.0000128042.28877.C3","volume":"62","author":"JH Yeh","year":"2004","unstructured":"Yeh JH, Chen WH, Chiu HC et al (2004) Low frequency of MuSK antibody in generalized seronegative myasthenia gravis among Chinese. Neurology 62(11):2131\u20132132","journal-title":"Neurology"},{"issue":"7","key":"6933_CR64","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1016\/S0929-6646(08)60171-0","volume":"107","author":"YC Huang","year":"2008","unstructured":"Huang YC, Yeh JH, Chiu HC et al (2008) Clinical characteristics of MuSK antibody-positive myasthenia gravis in Taiwan. J Formos Med Assoc 107(7):572\u2013575","journal-title":"J Formos Med Assoc"},{"issue":"1","key":"6933_CR65","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1111\/nyas.13518","volume":"1412","author":"A Evoli","year":"2018","unstructured":"Evoli A, Alboini PE, Damato V et al (2018) Myasthenia gravis with antibodies to MuSK: an update. Ann N Y Acad Sci 1412(1):82\u201389","journal-title":"Ann N Y Acad Sci"},{"issue":"51","key":"6933_CR66","doi-asserted-by":"publisher","first-page":"20783","DOI":"10.1073\/pnas.1313944110","volume":"110","author":"MG Huijbers","year":"2013","unstructured":"Huijbers MG, Zhang W, Klooster R et al (2013) MuSK IgG4 autoantibodies cause myasthenia gravis by inhibiting binding between MuSK and Lrp4. Proc Natl Acad Sci USA 110(51):20783\u201320788","journal-title":"Proc Natl Acad Sci USA"},{"key":"6933_CR67","doi-asserted-by":"publisher","first-page":"776","DOI":"10.3389\/fimmu.2020.00776","volume":"11","author":"ML Fichtner","year":"2020","unstructured":"Fichtner ML, Jiang R, Bourke A et al (2020) Autoimmune pathology in myasthenia gravis disease subtypes is governed by divergent mechanisms of immunopathology. Front Immunol 11:776","journal-title":"Front Immunol"},{"issue":"7","key":"6933_CR68","doi-asserted-by":"publisher","first-page":"e41561","DOI":"10.1371\/journal.pone.0041561","volume":"7","author":"K Wang","year":"2012","unstructured":"Wang K, Yuan Y, Cho JH et al (2012) Comparing the microRNA spectrum between serum and plasma. PLoS ONE 7(7):e41561","journal-title":"PLoS ONE"},{"issue":"9","key":"6933_CR69","doi-asserted-by":"publisher","first-page":"102349","DOI":"10.1016\/j.autrev.2019.102349","volume":"18","author":"H Zhong","year":"2019","unstructured":"Zhong H, Zhao C, Luo S (2019) HLA in myasthenia gravis: from superficial correlation to underlying mechanism. Autoimmun Rev 18(9):102349","journal-title":"Autoimmun Rev"},{"issue":"1","key":"6933_CR70","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1111\/imr.12398","volume":"271","author":"N Kurd","year":"2016","unstructured":"Kurd N, Robey EA (2016) T-cell selection in the thymus: a spatial and temporal perspective. Immunol Rev 271(1):114\u2013126","journal-title":"Immunol Rev"},{"key":"6933_CR71","doi-asserted-by":"publisher","first-page":"620894","DOI":"10.3389\/fimmu.2020.620894","volume":"11","author":"T Nitta","year":"2021","unstructured":"Nitta T, Takayanagi H (2021) Non-epithelial thymic stromal cells: unsung heroes in thymus organogenesis and T cell development. Front Immunol 11:620894","journal-title":"Front Immunol"},{"issue":"1\u20132","key":"6933_CR72","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.dci.2011.12.013","volume":"39","author":"D Ma","year":"2013","unstructured":"Ma D, Wei Y, Liu F (2013) Regulatory mechanisms of thymus and T cell development. Dev Comp Immunol 39(1\u20132):91\u2013102","journal-title":"Dev Comp Immunol"},{"issue":"3","key":"6933_CR73","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1002\/ana.410280303","volume":"28","author":"N Sommer","year":"1990","unstructured":"Sommer N, Willcox N, Harcourt GC, Newsom-Davis J (1990) Myasthenic thymus and thymoma are selectively enriched in acetylcholine receptor-reactive T cells. Ann Neurol 28(3):312\u2013319","journal-title":"Ann Neurol"},{"key":"6933_CR74","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.expneurol.2015.02.010","volume":"270","author":"A Marx","year":"2015","unstructured":"Marx A, Porubsky S, Belharazem D (2015) Thymoma related myasthenia gravis in humans and potential animal models. Exp Neurol 270:55\u201365","journal-title":"Exp Neurol"},{"issue":"3","key":"6933_CR75","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1016\/j.athoracsur.2008.04.070","volume":"86","author":"J Nakajima","year":"2008","unstructured":"Nakajima J, Murakawa T, Fukami T et al (2008) Postthymectomy myasthenia gravis: relationship with thymoma and antiacetylcholine receptor antibody. Ann Thorac Surg 86(3):941\u2013945","journal-title":"Ann Thorac Surg"}],"container-title":["Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-023-06933-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10072-023-06933-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-023-06933-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,12]],"date-time":"2023-10-12T04:09:59Z","timestamp":1697083799000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10072-023-06933-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,5]]},"references-count":75,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["6933"],"URL":"https:\/\/doi.org\/10.1007\/s10072-023-06933-3","relation":{},"ISSN":["1590-1874","1590-3478"],"issn-type":[{"type":"print","value":"1590-1874"},{"type":"electronic","value":"1590-3478"}],"subject":[],"published":{"date-parts":[[2023,7,5]]},"assertion":[{"value":"25 December 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 June 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 July 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"None.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}